Managing lymphoma with non-FDG radiotracers: current clinical and preclinical applications
- PMID: 23841079
- PMCID: PMC3690206
- DOI: 10.1155/2013/626910
Managing lymphoma with non-FDG radiotracers: current clinical and preclinical applications
Abstract
Nuclear medicine imaging modalities such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) have played a prominent role in lymphoma management. PET with [(18)F]Fluoro-2-deoxy-D-glucose (FDG) is the most commonly used tool for lymphoma imaging. However, FDG-PET has several limitations that give the false positive or false negative diagnosis of lymphoma. Therefore, development of new radiotracers with higher sensitivity, specificity, and different uptake mechanism is in great demand in the management of lymphoma. This paper reviews non-FDG radiopharmaceuticals that have been applied for PET and SPECT imaging in patients with different types of lymphoma, with attention to diagnosis, staging, therapy response assessment, and surveillance for disease relapse. In addition, we introduce three radiolabeled anti-CD20 antibodies for radioimmunotherapy, which is another important arm for lymphoma treatment and management. Finally, the relatively promising radiotracers that are currently under preclinical development are also discussed in this paper.
Figures


Similar articles
-
The role of FDG-PET imaging in the management of lymphoma.Clin Adv Hematol Oncol. 2004 Feb;2(2):115-21. Clin Adv Hematol Oncol. 2004. PMID: 16163171 Review.
-
Positron emission tomography in lymphoma: comparison with computed tomography and Gallium-67 single photon emission computed tomography.Clin Lymphoma. 2000 Jun;1(1):67-74; discussion 75-6. doi: 10.3816/clm.2000.n.007. Clin Lymphoma. 2000. PMID: 11707816 Review.
-
Imaging: staging and evaluation of lymphoma using nuclear medicine.Semin Oncol. 2005 Feb;32(1 Suppl 1):S11-8. doi: 10.1053/j.seminoncol.2005.01.009. Semin Oncol. 2005. PMID: 15786021
-
18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.Invest Radiol. 2016 Mar;51(3):163-9. doi: 10.1097/RLI.0000000000000218. Invest Radiol. 2016. PMID: 26784400 Free PMC article.
-
Role of Radiomics-Based Baseline PET/CT Imaging in Lymphoma: Diagnosis, Prognosis, and Response Assessment.Mol Imaging Biol. 2022 Aug;24(4):537-549. doi: 10.1007/s11307-022-01703-7. Epub 2022 Jan 14. Mol Imaging Biol. 2022. PMID: 35031945 Review.
Cited by
-
The Role of 11C-Methionine PET Imaging for the Evaluation of Lymphomas: A Systematic Review.Hematol Rep. 2024 Nov 27;16(4):752-768. doi: 10.3390/hematolrep16040072. Hematol Rep. 2024. PMID: 39728002 Free PMC article. Review.
-
Medical Imaging Technology and Imaging Agents.Adv Exp Med Biol. 2023;1199:15-38. doi: 10.1007/978-981-32-9902-3_2. Adv Exp Med Biol. 2023. PMID: 37460725
-
Recent Trends in PET Image Interpretations Using Volumetric and Texture-based Quantification Methods in Nuclear Oncology.Nucl Med Mol Imaging. 2014 Mar;48(1):1-15. doi: 10.1007/s13139-013-0260-2. Epub 2014 Jan 22. Nucl Med Mol Imaging. 2014. PMID: 24900133 Free PMC article. Review.
-
Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture.Cancers (Basel). 2019 Aug 31;11(9):1282. doi: 10.3390/cancers11091282. Cancers (Basel). 2019. PMID: 31480470 Free PMC article. Review.
-
Pretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistry.Front Med (Lausanne). 2014 Nov 18;1:44. doi: 10.3389/fmed.2014.00044. eCollection 2014. Front Med (Lausanne). 2014. PMID: 25593917 Free PMC article. Review.
References
-
- National Cancer Institute Surveillance. E.a.E.R.S.P. SEER stat fact sheets: lymphoma . 2011, http://seer.cancer.gov/statfacts/html/lymph.html.
-
- Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. The New England Journal of Medicine. 1998;339(1):21–26. - PubMed
-
- Horning SJ, Hoppe RT, Mason J, et al. Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin’s disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. Journal of Clinical Oncology. 1997;15(5):1736–1744. - PubMed
-
- Vermoolen MA, Kersten MJ, Fijnheer R, van Leeuwen MS, Kwee TC, Nievelstein RAJ. Magnetic resonance imaging of malignant lymphoma. Expert Review of Hematology. 2011;4(2):161–171. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical